Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 10/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 10/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566341 | 0.78 | HSP90AA1 (0.62) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL13609408 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL17049896 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL19519357 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL10306487 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL10306500 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL6936704 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL13621124 | 0.72 | HSP90AA1 (0.78) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL19519526 | 0.72 | POLB (0.63) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 | |
| SCHEMBL21363089 | 0.72 | HSP90AA1 (0.68) | LMNAMAP1LC3BMAP1LC3AHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-114191566-B | Method for preparing ZIF-8 composite nano material with magnetic targeting, antibacterial and developing functions | 上海交通大学 | 2023-09-29 | — | — | CN | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | claimed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | claimed |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | claimed |
| EP-0800394-A4 | PREVENTION OF ADVERSE BEHAVIOUR, DIARRHOEA, SKIN DISORDERS AND INFECTIONS OF THE HIND GUT ASSOCIATED WITH ACIDIC CONDITIONS IN HUMANS AND ANIMALS | ROWE JAMES BABER (AU) | 2001-06-27 | — | — | EP | claimed |
| EP-1017402-A4 | CONTROL OF ACIDIC GUT SYNDROME | UNIV NEW ENGLAND (AU) | 2001-05-30 | — | — | EP | claimed |
| EP-1017402-A1 | CONTROL OF ACIDIC GUT SYNDROME | UNIVERSITY OF NEW ENGLAND (AU) | 2000-07-12 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999000136-A1 | CONTROL OF ACIDIC GUT SYNDROME | THE UNIVERSITY OF NEW ENGLAND (AU) | 1999-01-07 | — | — | WO | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0800394-A1 | PREVENTION OF ADVERSE BEHAVIOUR, DIARRHOEA, SKIN DISORDERS AND INFECTIONS OF THE HIND GUT ASSOCIATED WITH ACIDIC CONDITIONS IN HUMANS AND ANIMALS | Rowe, James Baber (AU) | 1997-10-15 | — | — | EP | claimed |
| WO-1996020709-A1 | PREVENTION OF ADVERSE BEHAVIOUR, DIARRHOEA, SKIN DISORDERS AND INFECTIONS OF THE HIND GUT ASSOCIATED WITH ACIDIC CONDITIONS IN HUMANS AND ANIMALS | ROWE JAMES BABER (AU) | 1996-07-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | LMNA 1773/4885MAP1LC3B 2975/4885MAP1LC3A 3485/4885 |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | ABCC1, TSG101, BRCA1 | LMNA 4476/4885MAP1LC3B 2762/4885MAP1LC3A 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.